Company news
Compugen Ltd. (NASDAQ:CGEN) news
Every Compugen Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Compugen Reports Second Quarter 2026 Results
August 3, 2026
Compugen to Participate in BTIG Biotechnology Conference 2026
July 21, 2026
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
July 20, 2026
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
June 18, 2026
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
June 11, 2026
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
June 8, 2026
Compugen Reports First Quarter 2026 Results
May 18, 2026
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
May 12, 2026
Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026
May 4, 2026
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
April 9, 2026
Compugen Reports Fourth Quarter and Full Year 2025 Results
March 2, 2026
Compugen to Participate in Upcoming Investor Conferences
February 19, 2026
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
February 17, 2026
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
February 12, 2026
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
December 17, 2025
Compugen Reports Third Quarter 2025 Results
November 10, 2025
Compugen to Participate in Stifel 2025 Healthcare Conference
November 4, 2025
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
October 27, 2025
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
October 13, 2025
Compugen to Present at SITC 2025
October 6, 2025
Compugen to Present Research at the Single Cell Genomics 2025 Conference
September 8, 2025
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 28, 2025
Compugen Reports Second Quarter 2025 Results
August 6, 2025
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
July 28, 2025
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
July 23, 2025
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
July 21, 2025
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
June 12, 2025
Compugen Reports First Quarter 2025 Results
May 19, 2025
Compugen Announces Leadership Transitions Effective September 2025
May 13, 2025
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
May 5, 2025
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
March 26, 2025
/C O R R E C T I O N -- Compugen Ltd./
March 4, 2025
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
March 3, 2025
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Te...
February 26, 2025
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
February 18, 2025
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 4, 2025
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab i...
January 8, 2025
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGI...
November 27, 2024
Compugen Reports Third Quarter 2024 Results
November 12, 2024
Compugen to Participate in Stifel 2024 Healthcare Conference
November 11, 2024
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resista...
November 5, 2024
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 29, 2024
Compugen to Present New Clinical Data at SITC 2024
October 7, 2024
Compugen to Present at Single Cell Genomics 2024 Conference
September 9, 2024
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 29, 2024
Compugen Reports Second Quarter 2024 Results
August 6, 2024
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
July 29, 2024
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
July 23, 2024
Compugen to Present at Upcoming Antibody Industrial Symposium
June 17, 2024
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
May 30, 2024